Vol 72, No 1 (2022)
Letter to the Editor
Published online: 2021-12-13

open access

Page views 5301
Article views/downloads 288
Get Citation

Connect on Social Media

Connect on Social Media

Is the elimination of cervical cancer now 3 times easier? One-dose vaccine efficacy has far-reaching implications

Paweł Koczkodaj1, Joakim Dillner2, Marta Manczuk1
Nowotwory. Journal of Oncology 2022;72(1):65-66.


Not available

Article available in PDF format

View PDF Download PDF file


  1. Kunitoki K, Funato M, Mitsunami M, et al. Access to HPV vaccination in Japan: Increasing social trust to regain vaccine confidence. Vaccine. 2021; 39(41): 6104–6110.
  2. Karafillakis E, Simas C, Jarrett C, et al. HPV vaccination in a context of public mistrust and uncertainty: a systematic literature review of determinants of HPV vaccine hesitancy in Europe. Hum Vaccin Immunother. 2019; 15(7-8): 1615–1627.
  3. Troiano G, Nardi A. Vaccine hesitancy in the era of COVID-19. Public Health. 2021; 194: 245–251.
  4. Basu P, Malvi S, Joshi S, et al. Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study. The Lancet Oncology. 2021; 22(11): 1518–1529.
  5. Garland SM, Stanley MA, Giuliano AR, et al. IPVS Policy Committee. IPVS statement on "Temporary HPV vaccine shortage: Implications globally to achieve equity". Papillomavirus Res. 2020; 9: 100195.
  6. Bosch FX, Robles C, Díaz M, et al. HPV-FASTER: broadening the scope for prevention of HPV-related cancer. Nat Rev Clin Oncol. 2016; 13(2): 119–132.
  7. Dillner J, Elfström KM, Baussano I. Prospects for accelerated elimination of cervical cancer. Prev Med. 2021; 153: 106827.

Nowotwory. Journal of Oncology